Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation
Table 1
Clinical characteristics of 65 glioma patients.
Characteristics
Pseudoprogression (n = 14)
True progression (n = 51)
t/X2
value
Mean age ± SD(years)
43.640 ± 14.372
47.290 ± 14.375
−0.842
0.403
Gender
0.022
0.881
Male
8
28
Female
6
23
1p19q codeletion(+) (n = 23)
1(33.33%)
4(21.05%)
—
0.814
Promoter of MGMT methylation (n = 12)
1(33.33%)
5(55.56%)
—
0.574
IDH mutation (n = 13)
1(50.00%)
3(27.27%)
—
0.178
WHO grading
—
0.451
II
1
3
III
9
24
IV
4
24
KPS score
−1.427
0.154
Median
90.000
90.000
95%CI
90.000–90.000
86.890–89.580
T2-FLAIR mismatch
—
0.676
Yes
1
9
No
13
42
Enhancement of residual cavity wall
—
0.001
Thin-linear
11
12
Thick-linear
1
10
Nodular
2
29
Total dose (GyRBE)
−0.503
0.615
Median
60
59.92
95%CI
55.761–60.502
57.669–59.462
SVZ involvement
—
0.204
Yes
7
36
No
7
15
ADC mean (mm2/s) (n = 54)
903.142 ± 491.652
523.000 (484.950–668.610)
−1.842
0.067
MGMT, O6-methyl-guanine methyl transferase; KPS, Karnofsky Performance Score; SVZ, subventricular zone; ADC mean, apparent diffusion coefficient mean; T2-FLAIR mismatch, the presence of a complete/near-complete hyperintense signal on T2-weighted (T2W) MRI sequences, in combination with a relative hypointense signal on fluid attenuation inversion recovery (FLAIR) MR sequences except for a hyperintense peripheral rim; Bold value indicates statistically significant association, - indicates Fisher’s exact test.
